Ovid Therapeutics INC 10-Q quarterly reports

Ovid Therapeutics Inc. filed its Form 10-Q for the period ended June 30, 2026, detailing continued operating losses and a strong reliance on capital raises to fund its biopharmaceutical development.

Ovid Therapeutics Inc. reported its first quarter 2026 financial results, highlighting increased research and development expenses and significant proceeds from private placements and warrant exercises.

Ovid Therapeutics reported a net loss of $12.2 million for Q3 2025, but a recent $75.7 million private placement significantly extends its cash runway.

Ovid Therapeutics reported increased net losses and substantial doubt about its ability to continue as a going concern, despite a one-time revenue boost from a licensing agreement.

Ovid Therapeutics reports a net loss of $10.2 million for Q1 2025, focusing on pipeline development and managing cash runway.

Ovid Therapeutics' third quarter 2024 report highlights ongoing research and development efforts, alongside a strategic restructuring to extend its cash runway.

Ovid Therapeutics reported a net income of $8.5 million for the second quarter of 2024, primarily due to an adjustment in a royalty monetization liability, while also announcing a significant workforce reduction.

Ovid Therapeutics reported a net loss of $11.7 million for the first quarter of 2024, while progressing its clinical development programs for OV329 and OV888.